Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613000158763
Ethics application status
Approved
Date submitted
4/01/2013
Date registered
11/02/2013
Date last updated
31/03/2014
Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluating treatment efficacy of citalopram, symbiotic, and mebeverine for children with functional abdominal pain.
Scientific title
Evaluation treatment efficacy of citalopram, synbiotic, and mebeverine for children with functional abdominal pain; a randomized, placebo-controlled study.
Secondary ID [1] 281783 0
391299
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Children's functional abdominal pain 287888 0
Children mental health 288035 0
Condition category
Condition code
Oral and Gastrointestinal 288267 288267 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Mental Health 288408 288408 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
In citalopram group children take oral citalopram tablet 10 mg/day for one week and then 20 mg/day for three weeks.
In mebeverine group children take oral mebeverine tablet 135 mg/twice daily for four weeks.
In symbiotic group children take oral Lactol tablet (150 million spores + 100 mg FOS) twice daily for four weeks.
In placebo group children take oral placebo tablet twice daily for four weeks.
Intervention code [1] 286141 0
Treatment: Drugs
Comparator / control treatment
One placebo tablet( identical in taste and appearance to citalopralm,Lactol and mebeverin but without the active ingredient) twice a day for 4weeks
Control group
Placebo

Outcomes
Primary outcome [1] 288443 0
Clinical Global Impression-Global Improvement (CGI-I)

For detecting the abdominal pain improvement.
Timepoint [1] 288443 0
At the end of treatment (week four)
Primary outcome [2] 288636 0
clinical Global Impression-severity(CGI-S)

To detect changing in severity of abdominal pain
Timepoint [2] 288636 0
At the end of 4 weeks
Primary outcome [3] 288637 0
Wang-Baker Faces Pain Rating Score

To detect changing in abdominal pain rate
Timepoint [3] 288637 0
At the end of four weeks
Secondary outcome [1] 300172 0
Clinical Global Impression-Global Improvement (CGI-I)

For detecting the abdominal pain improvement
Timepoint [1] 300172 0
12 weeks after the end of treatment
Secondary outcome [2] 300675 0
clinical Global Impression-severity(CGI-S)

To detect changing in severity of abdominal pain
Timepoint [2] 300675 0
12 weeks after the end of treatment
Secondary outcome [3] 300676 0
Wang-Baker Faces Pain Rating Score

To detect changing in abdominal pain rate
Timepoint [3] 300676 0
12 weeks afte the e d of treatment

Eligibility
Key inclusion criteria
Children between 6 to 18 years old, having functional abdominal pain according to ROME III criteria, having not consumption of probiotics and antibiotics in previous 2 months
Minimum age
6 Years
Maximum age
18 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Having gasterointestinal problems rather than functional abdomainal pain,

Patients who will not use three tablets

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 2 / Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
29/11/2012
Actual
25/03/2013
Date of last participant enrolment
Anticipated
Actual
16/12/2013
Date of last data collection
Anticipated
Actual
Sample size
Target
200
Accrual to date
Final
Recruitment outside Australia
Country [1] 4775 0
Iran, Islamic Republic Of
State/province [1] 4775 0
Isfahan

Funding & Sponsors
Funding source category [1] 286519 0
University
Name [1] 286519 0
Isfahan university of medical siences
Country [1] 286519 0
Iran, Islamic Republic Of
Primary sponsor type
University
Name
Isfahan University of medical silences
Address
Isfahan university of medical siences, Hezarjarib Ave,Isfahan,Iran

Postcode: 81647-2384
Country
Iran, Islamic Republic Of
Secondary sponsor category [1] 285352 0
Other
Name [1] 285352 0
Child health promotion research center
Address [1] 285352 0
Emam hosein children hospital,Emam Khomeini Ave, Isfahan ,Iran.

Post code :81577-2342
Country [1] 285352 0
Iran, Islamic Republic Of

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 288592 0
Ethics committe of Isfahan University of Medical Sciences
Ethics committee address [1] 288592 0
Ethics committee country [1] 288592 0
Iran, Islamic Republic Of
Date submitted for ethics approval [1] 288592 0
06/08/2012
Approval date [1] 288592 0
06/09/2012
Ethics approval number [1] 288592 0
391299

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 35000 0
Dr Zahra Pourmoghaddas
Address 35000 0
Emam Hosein Children Hospital,Emam Khomeini Ave, Isfahan,iran.

Post code:81577-2342
Country 35000 0
Iran, Islamic Republic Of
Phone 35000 0
+989131864168
Fax 35000 0
Email 35000 0
Zahrapormoghadas@yahoo.com
Contact person for public queries
Name 18247 0
Zahra Pourmoghaddas
Address 18247 0
Emam Hosein Children Hospital,Emam Khomeini Ave, Aisfahan,Iran

81577-2342
Country 18247 0
Iran, Islamic Republic Of
Phone 18247 0
+989131864168
Fax 18247 0
Email 18247 0
Zahrapormoghadas@yahoo.com
Contact person for scientific queries
Name 9175 0
Zahra Pourmoghaddas
Address 9175 0
Emam Hosein Children Hospital,Emam Khomeini Ave, Aisfahan,Iran

Post code:81577-2342
Country 9175 0
Iran, Islamic Republic Of
Phone 9175 0
+989131864168
Fax 9175 0
Email 9175 0
Zahrapormoghadas@yahoo.com

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.